



Supplement of

Comparison of surgical treatments for hip and knee periprosthetic joint infections using the desirability of outcome ranking in a prospective multicentre study

Brenton P. Johns et al.

Correspondence to: Joshua S. Davis (joshua.davis@health.nsw.gov.au)

The copyright of individual parts of the supplement might differ from the article licence.

Table S1: Demographics of cohort with 12-month DOOR Data

	Overall Cohort
Patients (<i>n</i>)	574
Knee (<i>n</i>)	334
Hip (<i>n</i>)	240
Age (yrs), mean	69.2
M:F (<i>n</i>)	334:240
Side Right:Left (<i>n</i>)	334:240
Time post implant (days)*	322
Surgical strategy	
DAIR (<i>n</i>)	318
2-stage revision (<i>n</i>)	146
Suppression (<i>n</i>)	62
1-stage revision (<i>n</i>)	33
Excision arthroplasty (<i>n</i>)	15
Clinical Presentation	
Symptom duration (days)*	4
Symptoms <7 days (<i>n</i>)	371
Joint Inflammation (<i>n</i>)	459
Fever (<i>n</i>)	236
Sepsis (<i>n</i>)	27
Comorbidities	
Rheumatoid arthritis (<i>n</i>)	37
Diabetes (<i>n</i>)	129
Chronic Renal Failure (<i>n</i>)	42
Liver Cirrhosis (<i>n</i>)	6
Ischaemic heart disease (<i>n</i>)	97
Malignancy (<i>n</i>)	23
Heart Failure (<i>n</i>)	38
Steroid use (<i>n</i>)	48
Immunosuppressants (<i>n</i>)	30
Laboratory Results	
WCC ($\times 10^9/L$)*	11.5
Neutrophils ($\times 10^9/L$)*	8.8
CRP (g/L)*	181
Albumin (g/L)	31
Microbiology	
Monomicrobial (<i>n</i>)	397
Polymicrobial (<i>n</i>)	129
Culture negative (<i>n</i>)	48
MSSA (<i>n</i>)	224
MRSA (<i>n</i>)	17
CoNS (<i>n</i>)	122
Enterococcus (<i>n</i>)	38
Streptococcus (<i>n</i>)	138
Gram negative (<i>n</i>)	89

*Values given as medians




Figure S1: DOOR distribution at 12-month follow-up